JANNEY DANIEL
Known title: DirectorCIK: 0001198325
Associated companies
Transaction History
| KRYS | ▼ Sell | Open Market | 9,430 | $2.6M | 2/27/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 2,373 | $655K | 2/27/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 5,103 | $1.4M | 2/26/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 2,638 | $729K | 2/26/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 700 | $193K | 2/25/2026 | View on chart |
| KRYS | ▲ Buy | Option Exercise | 37,895 | $93K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 569 | $150K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 1,733 | $458K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 3,557 | $943K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 8,986 | $2.4M | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 11,673 | $3.1M | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 6,671 | $1.8M | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 3,963 | $1.1M | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 370 | $100K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 373 | $101K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 62 | $16K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 900 | $238K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 1,604 | $426K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 4,339 | $1.2M | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 1,891 | $506K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 1,674 | $450K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 930 | $251K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 2,425 | $667K | 2/24/2026 | View on chart |
| KRYS | ▼ Sell | Open Market | 3,935 | $509K | 6/9/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 5,000 | $644K | 6/9/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 10,000 | $1.3M | 6/9/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 4,604 | $589K | 6/8/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 1,073 | $138K | 6/8/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 5,388 | $694K | 6/8/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 5,000 | $640K | 6/8/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 10,000 | $1.3M | 6/8/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 5,000 | $639K | 6/8/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 50,000 | $4.8M | 5/19/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 17,100 | $1.6M | 5/9/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 7,900 | $713K | 4/19/2023 | View on chart |
| KRYS | ▼ Sell | Open Market | 100,000 | $7.0M | 12/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Krystal Biotech: Analysts Question Durability of Rare-Disease Drug Moat
Recent analysis focuses on whether Krystal Biotech's rare-disease drug has a durable competitive advantage. This question is relevant as the stock trades near its 52-week high, with a trailing P/E of 39.5. The current price action shows a support rejection, indicating potential short-term volatility.
Krystal Biotech: Analysts Question Durability of Rare-Disease Drug Moat. Recent analysis focuses on whether Krystal Biotech's rare-disease drug has a durable competitive advantage. This question is relevant as the stock trades near its 52-week high, with a trailing P/E of 39.5. The current price action shows a support rejection, indicating potential short-term volatility.